MedTrace Logo

Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

NCT02424955 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to prospectively analyze the value of 3D ultrasound perfusion imaging for treatment planning, the prediction of therapy success, and to monitor the treatment response in patients with a primary or metastatic liver tumor undergoing radiation treatment.

Conditions

Interventions

DRUG

perflutren lipid microspheres

DIAGNOSTIC_TEST

3D ultrasound

Sponsors & Collaborators

Principal Investigators

  • Daniel T. Chang · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-18
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424955 on ClinicalTrials.gov